BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 183576)

  • 1. Cholestyramine: an effective, twice-daily dosage regimen.
    Blum CB; Havlik RJ; Morganroth J
    Ann Intern Med; 1976 Sep; 85(3):287-9. PubMed ID: 183576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-effect relation of cholestryamine in children and young adults with familial hypercholesterolaemia.
    Farah JR; Kwiterovich PO; Neill CA
    Lancet; 1977 Jan; 1(8002):59-63. PubMed ID: 63709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholestyramine in type IIa hyperlipoproteinemia. Is low-dose treatment feasible?
    Angelin B; Einarsson K
    Atherosclerosis; 1981; 38(1-2):33-8. PubMed ID: 7470203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the dose-effect relationship of cholestyramine in children with familial hypercholesterolemia.
    Farah JR; Kwiterovich PO; Neill CA
    Adv Exp Med Biol; 1977; 82():212-5. PubMed ID: 200092
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy of familial hypercholesterolemia in childhood: diet and cholestyramine resin for 24 to 36 months.
    Glueck CJ; Tsang RC; Fallat RW; Mellies M
    Pediatrics; 1977 Mar; 59(3):433-41. PubMed ID: 840563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholestyramine plus pectin in treatment of patients with familial hypercholesterolemia.
    Schwandt P; Richter WO; Weisweiler P; Neureuther G
    Atherosclerosis; 1982 Sep; 44(3):379-83. PubMed ID: 7150399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.
    Series JJ; Caslake MJ; Kilday C; Cruickshank A; Demant T; Lorimer AR; Packard CJ; Shepherd J
    Metabolism; 1989 Feb; 38(2):153-8. PubMed ID: 2643751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia.
    Mann JI; Harding PA; Turner RC; Wilkinson RH
    Br J Clin Pharmacol; 1977 Jun; 4(3):305-8. PubMed ID: 197982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
    Therapie; 1978; 33(5):615-22. PubMed ID: 217121
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma vitamin A and E levels in children with familial type II hyperlipoproteinemia during therapy with diet and cholestyramine resin.
    Glueck CJ; Tsang RC; Fallat RW; Scheel D
    Pediatrics; 1974 Jul; 54(1):51-5. PubMed ID: 4365953
    [No Abstract]   [Full Text] [Related]  

  • 12. Cholestyramine for elevated serum cholesterol.
    Med Lett Drugs Ther; 1974 Apr; 16(8):33-4. PubMed ID: 4362570
    [No Abstract]   [Full Text] [Related]  

  • 13. Cholestyramine in hypercholesterolaemia.
    West R; Lloyd JK
    Lancet; 1977 Feb; 1(8009):488-9. PubMed ID: 65596
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
    Stein E; Kreisberg R; Miller V; Mantell G; Washington L; Shapiro DR
    Arch Intern Med; 1990 Feb; 150(2):341-5. PubMed ID: 2405804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.
    JAMA; 1988 Jul; 260(3):359-66. PubMed ID: 2898027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypercholesterolemia with Secholex. A long-term clinical trial and comparison with cholestyramine.
    Nikkila EA; Miettinen TA; Lanner A
    Atherosclerosis; 1976 Sep; 24(3):407-19. PubMed ID: 971343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial.
    Pflugfelder PW; Huff M; Oskalns R; Rudas L; Kostuk WJ
    J Heart Lung Transplant; 1995; 14(4):613-22. PubMed ID: 7578166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
    Jover E; Aranda JL; Nogués X; del Palacio A; Rubiés-Prat J
    Med Clin (Barc); 1996 May; 106(20):776-9. PubMed ID: 8801396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudohomozygous type II hyperlipoproteinemia.
    Morganroth J; Levy RI; McMahon AE; Gotto AM
    J Pediatr; 1974 Nov; 85(5):639-43. PubMed ID: 4370845
    [No Abstract]   [Full Text] [Related]  

  • 20. [The efficacy of cholestyramine as a hypocholesterolemic agent and its tolerance in a Mexican population].
    Lerman Garber I; Cardoso Saldaña G; Zamora González J; Ahumada Ayala M; García Rubí E; Posadas Romero C
    Arch Inst Cardiol Mex; 1991; 61(1):47-51. PubMed ID: 2048910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.